The DRAGON 2 Trial

Korábbi kezelés

• Complete response after conversion chemotherapy

Más betegség

• Any patient with non-resectable or non-ablatable extrahepatic disease
• Patients with hepatic malignancies other than CRLM
• Progression of disease by RECIST criteria after cytoreduction chemotherapy
• Staging CT and (if indicated) CT/MRI brain that demonstrates non-resectable extrahepatic disease

Egyéb

• Pregnant or lactating female.
• Premenopausal females not able or willing to commit to oral contraception
• Patients with prohibitive comorbidities, decision made by local team
• The anatomy of the liver or manifestation of tumors in relation to the liver veins prohibits the use of combined PVE/HVE.

• Patients with primarily unresectable/ potentially resectable CRLM with a FLR <30% (<40% in chemotherapy damaged livers)
• Patients with non-resected primary CRC may be included if there is an intention to resect the CRC after the liver treatment (liver first approach) or simultaneously during one of the liver procedures.
• Patients with resectable or ablatable lung or brain metastases can be included (statement about the resectability of these extrahepatic metastases by a tumor board needs to be available)
• 18 Years and older
• Men and women
• Able to understand the trial and provide informed consent.